J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on December 1, 2006

Papers In Press, published online ahead of print September 11, 2006
J. Lipid Res., doi:10.1194/jlr.P600009-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
P600009-JLR200v1
47/12/2820    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarenbach, J. J.
Right arrow Articles by Sudhop, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarenbach, J. J.
Right arrow Articles by Sudhop, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on July 27, 2006
Revised on September 5, 2006
Accepted on September 7, 2006

The lipid-lowering effect of ezetimibe in pure vegetarians

Jacob J. Clarenbach, Michael Reber, Dieter Lutjohann, Klaus von Bergmann, and Thomas Sudhop

Scientific Service, Federal Institute for Drugs and Medical Devices, Bonn 53175

Corresponding Author: sudhop{at}bfarm.de

Background Results of previous studies have shown that ezetimibe (10 mg/day) reduces LDL cholesterol in patients with mild hypercholesterolemia on a normal cholesterol diet (dietary intake 200-500 mg/d) by 16 to 22 %. However, the LDL cholesterol-lowering effect of ezetimibe in subjects with an extremely low dietary cholesterol intake (vegetarians) has not been studied so far. Methods We conducted a randomized, double-blind, placebo-controlled, two-phase cross-over study in 18 healthy pure vegetarians to assess the effect of ezetimibe (10 mg/day) on plasma lipids, cholesterol absorption, and its synthesis. Treatment periods lasted 2 weeks each, with an intervening 2-week wash-out period. Fractional cholesterol absorption was determined using the continuous dual stable-isotope feeding method. Results Mean dietary cholesterol intake in the pure vegetarians was extremely low and averaged 29.4 ± 16.8 mg/day and 31.4 ± 14.4 mg/day during the placebo and ezetimibe administration phases, respectively. Fractional cholesterol absorption during placebo was 48.2 ± 8.2% and was lowered by -58% during ezetimibe treatment to 20.2 ± 6.2% (p<0.001). This change in intestinal cholesterol absorption was followed by a significant reduction in LDL cholesterol by 17.3%. Conclusion In individuals with extremely low dietary cholesterol intake, treatment with ezetimibe (10 mg/d) leads to a significant reduction of cholesterol absorption and clinically relevant decrease of plasma LDL cholesterol, comparable to subjects with a normal dietary cholesterol intake. Thus, the lipid-lowering effect of ezetimibe is mediated mainly through a reduction of the absorption of endogenous (biliary) cholesterol.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.